Founded In Hong Kong, Caring For The World
Our Purpose
We are focused on integrating cutting-edge multispectral sensors into portable spectroscopic devices, in conjunction with leading DNA damage biomarkers, to create an accessible early disease screening solution for the public.
Our goal is to revolutionize personal health monitoring and early disease screening. As a Hong Kong-based biotechnology company, we are developing and commercializing more sensitive, portable, and inclusive cancer early screening solutions to general public.
Our Story
We're a bio-tech company based in Hong Kong, focusing on using cutting-edge multispectral sensor tech in portable spectroscopic devices. We're combining top DNA damage biomarkers globally to create a real game-changer in disease early screening accessible to everyone. Our aim is to revolutionize personal health monitoring and early disease detection.
The Chemmino team comprises professors and doctors from top research institutions worldwide. Our founders have made significant breakthroughs in spectral sensors and DNA damage biomarkers. Working together at the University of Hong Kong, they realized the immense potential of merging these innovations. We've identified a huge demand in the early cancer detection market, where existing products are costly, painful, and cumbersome. This led our founders to collaborate in addressing this user pain point.
In 2023, Chemmino spun off from the Laboratory for Synthetic Chemistry and Chemical Biology Limited (LSCCB) funded by Health@InnoHK of HKSAR, diving into research and commercialization to swiftly offer various early disease detection solutions to those in need.
We believe that by predicting risks earlier, we can not only help the public reduce the burden of illness but also alleviate the strain on public institutions in cancer treatment, making society a better place.
Our Partners
Industry Investment
2 million HKD
University Support Schemes
1.25 million HKD
University Support Schemes
100k HKD
With the rapid progress and advancements within the team, Chemmino has achieved commendable results in just one year. Not only have we stood out in various incubation projects at HKU and HKSTP, but we have also gained the trust of industry investors. We firmly believe that with the help of top research institutions and investors worldwide, we will be able to deliver powerful, market-oriented products to the general public.
Our Team
Dr. Wei LIU
CEO | Co-founder
- Ph.D. from Yale University
- Honorary Research Professor, HKU Chemistry
- Co-founder, Vispek
- Co-founder, RxAll Inc.
Pro. Chi Ming CHE
CSO | Co-founder
- Head and Chair Professor, HKU Chemistry
- Academician, Chinese Academy of Sciences
- Foreign Associate, US National Academy of Sciences
Dr. Xin DAI
CTO | Co-founder
- Ph.D. from HKUST
- Postoral Fellow, HKUST
- Research Officer, LSCCB
Mr. Dakai GONG
CMO | Co-founder
- MSc from CUHK
- Marketing Director, Vispek
Prof. Xinguo ZHANG
Co-principal Investigator
- Southern Medical University Pharmaceutical Sciences
- World’s Top 2% Cited Scientists
Prof. Lingpeng KONG
Co-principal Investigator
- HKU Computer Science
Prof. Jinqing HUANG
Co-principal Investigator
- HKUST Chemistry
Dr. Ka Wai HUNG
Clinical Director
- MB ChB (CUHK), MRCSEd, FRCSEd(Gen), FCSHK, FHKAM (Surgery)